China & AstraZeneca
14 shared events · Importance 4 · Last updated Aug 24, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
China: The approval of ORPATHYS (savolitinib) in China addresses a significant unmet medical need for gastric cancer patients in the country, where gastric cancer is a leading cause of cancer death.
AstraZeneca: AstraZeneca, as HUTCHMED's partner, jointly developed and commercializes ORPATHYS (savolitinib). The approval in China for gastric cancer expands its market reach and reinforces its precision medicine strategy.
Jul 02, 2026 · 6 articles
International
China: China highlighted regenerative agriculture partnerships and autonomous logistics solutions.
AstraZeneca: AstraZeneca featured an AI-powered drug discovery platform, advancing precision diagnostics and treatment.
Jun 15, 2026 · 87 articles
Business
China: Zegfrovy is approved in China; CDE granted Breakthrough Therapy Designation for first-line use.
AstraZeneca: AstraZeneca expands its lung cancer portfolio with a novel oral EGFR inhibitor, complementing existing drugs like Tagrisso. The deal involves a $600M upfront payment and potential milestones, but does not affect 2026 guidance.
Jul 14, 2026 · 8 articles
Business
China: China is the home market of Sino Biopharmaceutical and the source of its innovative medicines. The company's globalization efforts may enhance China's reputation in the global pharmaceutical industry, but the direct market impact on China is limited.
AstraZeneca: AstraZeneca licensed TQC3721, an inhaled PDE3/4 inhibitor for COPD, from Sino Biopharmaceutical in a deal valued up to US$1.9 billion. This strengthens AstraZeneca's respiratory pipeline and aligns with its focus on chronic diseases.
Jul 20, 2026 · 6 articles
Accidents
China: Sent a third medical expert team to DRC, strengthening bilateral cooperation and global health engagement.
AstraZeneca: Technology from its COVID-19 vaccine is used in the Oxford Ebola vaccine, indirectly involved.
Aug 01, 2026 · 301 articles
Domestic
China: Donald Trump acknowledged that his tariffs against China had previously hurt American farmers, who lost out on soybean sales, indicating potential for renewed trade tensions.
AstraZeneca: AstraZeneca, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Business
China: AI startups surged on domestic chip developments. Potential U.S. import ban on components.
AstraZeneca: Investors punished the stock over merger talks with Bristol Myers Squibb.
Jul 14, 2026 · 280 articles
Accidents
China: China>>> is developing an mRNA vaccine that has shown promise against Uganda — Bundibugyo in mice and has pledged to send medical specialists to the Democratic Republic of the Congo>>> to assist with the outbreak.
AstraZeneca: AstraZeneca was involved in the development of the COVID-19 vaccine platform that is now being considered for a Bundibugyo ebolavirus vaccine, showcasing its role in vaccine innovation.
May 18, 2026 · 505 articles
International
China: China called for an end to hostilities and supports Pakistan's mediation. It is concerned about disruptions to trade routes and has economic interests in reopening the Strait of Hormuz.
AstraZeneca: AstraZeneca gained 1.3% after topping Q2 profit expectations.
Jul 08, 2026 · 472 articles
International
China: Ambassador met with Iranian officials; China is a major oil importer affected by Hormuz closure.
AstraZeneca: Pharmaceutical company, whose stock gained on higher oil prices.
Jul 28, 2026 · 318 articles
Business
China: Ascentage Pharma operates in China and has approvals from Chinese regulators, but this event does not directly impact the country.
AstraZeneca: AstraZeneca is a partner of Ascentage Pharma, but this event does not directly involve AstraZeneca.
Jul 26, 2026 · 6 articles
International
AstraZeneca: AstraZeneca announced a significant investment of $15 billion in China through 2030 to expand its medicines manufacturing and research, demonstrating confidence in the Chinese market.
Jan 30, 2026 · 9 articles
International
AstraZeneca: AstraZeneca's CEO, Pascal Soriot, is part of the business delegation, suggesting potential for increased pharmaceutical and healthcare sector cooperation with China.
Jan 27, 2026 · 34 articles
International
AstraZeneca: AstraZeneca executives participated in the Qingdao International City Partner Dialogue, engaging in discussions on sci-tech innovation and cooperation.
Jun 11, 2026 · 9 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how China and AstraZeneca interact across events, view sentiment trends, and discover connected entities.
Open Dashboard